Modulation of immune cell function following fluoxetine administration in rats

Pharmacology Biochemistry and Behavior

Volumn 59, Issue 1, 1998, Pages 151-157

  Pellegrino, Trisha C ^a   Bayer, Barbara M ^a  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute; Cell mediated immunity; Central; Chronic; Cytolytic activity; Fluoxetine; Lymphocytes; NK cells; Proliferation; Serotonin; Specific serotonin reuptake inhibitors; T cells

Indexed keywords

FLUOXETINE;

ANIMAL EXPERIMENT; ARTICLE; CELLULAR IMMUNITY; DEPRESSION; IMMUNOMODULATION; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; RAT; T LYMPHOCYTE;

ANALYSIS OF VARIANCE; ANIMALS; BODY WEIGHT; FLUOXETINE; IMMUNITY, CELLULAR; KILLER CELLS, NATURAL; LYMPHOCYTES; MALE; MICROINJECTIONS; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN UPTAKE INHIBITORS;

ANIMALIA;

EID: 0031973163     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(97)00382-1     Document Type: Article

References (52)

1. Artigas F. 5-HT and antidepressants. New views from microdialysis studies Trends Pharmacol. Sci. 14:1993;262.
2. 1A receptors inhibit T-lymphocyte function in vitro and cell-mediated immunity in vivo. J. Immunol. 153:1994;489-498.
3. Bayer B. M., Brehio R. M., Ding X. Z., Hernandez M. C. Enhanced susceptibility of the immune system to stress in morphine-tolerant rats. Brain Behav. Immunol. 8:1994;173-184.
4. Bayer B. M., Hernandez M. C., Ding X. Z. Tolerance and crosstolerance to the suppressive effects of cocaine and morphine on lymphocyte proliferation. Pharmacol. Biochem. Behav. 53:1996;227-234.
5. Berkeley M. B., Daussin S., Hernandez M., Bayer B. M. In vitro effects of cocaine, lidocaine, and monoamine uptake inhibitors on lymphocyte proliferative responses. Immunopharmacol. Immunotoxicol. 16:1994;165-178.
6. Bianchi M., Sacerdote P., Panerai A. E. Chlomipramine differently affects inflammatory edema and pain in the rat. Pharmacol. Biochem. Behav. 48:1994;1037-1040.
7. Bianchi M., Rossini G., Sacerdote P., Panerai A. E., Berti F. Effects of chlomipramine and fluoxetine in subcutaneous carrageenin-induced inflammation in the rat. Inflamm. Res. 44:1995;466-469.
8. Brandes L. J., Arron R. J., Bogdanovic R. P., Tong J., Zaborniak C. L. F., Hogg G. R., Warrington R. C., Fang W., LaBella F. S. Stimulation of malignant growth in rodents by antidepressant drugs at clinically relevant doses. Cancer Res. 52:1992;3796-3800.
9. Caccia S., Cappi M., Fracasso C., Garattini S. Influence of dose and route of administration on the kinetics of fluoxetine and its metabolite norfluoxetine in the rat. Psychopharmacology (Berlin). 100:1990;509-514.
10. Calabrese J. R., Kling M. A., Gold P. W. Alterations in immunocompetence during stress, bereavement, and depression. Focus on neuroendocrine regulation Am. J. Psychol. 144:1987;1123-1134.
11. 2 receptor downregulation. Eur. J. Pharmacol. 249:1993;117-120.
12. Checkley S. Neuroendocrine mechanisms and the precipitation of depression by life events. Br. J. Psychol. 60(Suppl. 15):1992;7-17.
13. Crowson A. N., Magro C. M. Antidepressant therapy. A possible cause of atypical cutaneous lymphoid hyperplasia Arch. Dermatol. 131:1995;925-929.
14. Evans D. L., Folds J. D., Petitto J. M., Golden R. N., Pedersen C. A., Corrigan M., Gilmore J. H., Silva S. G., Quade D., Ozer H. Circulating natural killer cell phenotypes in men and women with major depression. Relation to cytotoxic activity and severity of depression Arch. Gen. Psychol. 49:1992;388-395.
15. File S. E. Recent developments in anxiety, stress, and depression. Pharmacol. Biochem. Behav. 54:1996;3-12.
16. Fuchs E., Kramer M., Hermes B., Netter P., Hiemke C. Psychosocial stress in tree shrews. Clomipramine counteracts behavioral and endocrine changes Pharmacol. Biochem. Behav. 54:1996;219-228.
17. Graeff F. G., Guimaraes F. S., De Andrade T. G. C. S., Deakin J. F. W. Role of 5-HT in stress, anxiety, and depression. Pharmacol. Biochem. Behav. 54:1996;129-141.
18. Greenberg R. P., Bornstein R. F., Zborowski M. J., Fisher S., Greenberg M. D. A meta-analysis of fluoxetine outcome in the treatment of depression. J. Nerv. Ment. Dis. 182:1994;547-551.
19. 1A receptors in mice. Pharmacol. Biochem. Behav. 45:1993;65-70.
20. Hellstrand K., Hermodsson S. Role of serotonin in the regulation of human natural killer cell cytotoxicity. J. Immunol. 139:1987;869-875.
21. Hernandez M. C., Flores L. R., Bayer B. M. Immunosuppression by morphine is mediated by central pathways. J. Pharmacol. Exp. Ther. 267:1994;1336-1341.
22. Hickie I., Hickie C., Lloyd A., Silove D., Wakefield D. Impaired in vivo immune responses in patients with melancholia. Br. J. Psychol. 162:1993;651-657.
23. Hollister L. E., Claghorn J. L. New antidepressants. Annu. Rev. Pharmacol. Toxicol. 32:1993;165-177.
24. Holsboer F., Spengler D., Heuser I. The role of corticotropin-releasing hormone in the pathogenesis of Cushing's disease, anorexia nervosa, alcoholism, affective disorders and dementia. Prog. Brain Res. 93:1992;385-417.
25. Irwin M., Caldwell C., Smith T. L., Brown S., Schuckit M. A., Gillin J. C. Major depressive disorder, alcoholism, and reduced natural killer cell cytotoxicity. Arch. Gen. Psychol. 47:1990;713-719.
26. Irwin M., Daniels M., Bloom E. T., Smith T. L., Weiner H. Life events, depressive symptoms, and immune function. Am. J. Psychol. 144:1987;437-441.
27. Irwin M., Lacher U., Caldwell C. Depression and reduced natural killer cytotoxicity. A longitudinal study of depressed patients and control subjects Psychol. Med. 22:1992;1045-1050.
28. 2 receptors in P11 cells. J. Pharmacol. Exp. Ther. 259:1991;423-429.
29. Koe K. B., Weissman A., Welch W. M., Browne R. G. Sertraline, 1s,4s-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthylamine, a new uptake inhibitor with selectivity for serotonin. J. Pharmacol. Exp. Ther. 226:1983;686-700.
30. Kook A. I., Mizruchin A., Odnopozov N., Gershon H., Segev Y. Depression and immunity. The biochemical interrelationship between the central nervous system and the immune system Biol. Psychol. 37:1995;817-819.
31. 1C receptor density in the rat choroid plexus. Comparison with haloperidol J. Pharmacol. Exp. Ther. 264:1993;1262-1267.
32. Linkins R. W., Comstock G. W. Depressed mood and development of cancer. Am. J. Epidimiol. 132:1990;962-972.
33. Maes M., Stevens W., Peeters D., DeClerck L., Sharpe S., Bridts C., Schotte C., Cosyns P. A study on the blunted natural killer cell activity in severely depressed patients. Life Sci. 50:1992;505-513.
34. Malagie I., Trillat A., Jacquot C., Gardier A. M. Effects of acute fluoxetine on extracellular serotonin levels in the raphe. An in vivo microdialysis study Eur. J. Pharmacol. 286:1995;213-217.
35. Mohl P. C., Huang L., Bowden C., Fischbach M., Vogtsberger K., Talal N. Natural killer cell activity in major depression. Am. J. Psychol. 144:1987;1619.
36. Nordlind K., Sundstrom E., Bondesson L. Inhibiting effects of serotonin antagonists on the proliferation of mercuric chloride stimulated human peripheral blood T-lymphocytes. Int. Arch. Allergy Immunol. 97:1992;105-108.
37. Paxinos G., Watson C. Atlas of the rat brain. 1986;Academic Press, San Diego.
38. Paykel E. S. Contribution of life events to causation of psychiatric illness. Psychol. Med. 8:1978;245-253.
39. Persky V. W., Kempthorne-Rawson J., Shekelle R. B. Personality and risk of cancer. 20-year follow-up of the Western Electric study Psychosom. Med. 49:1987;435-449.
40. Potter W. Z., Rudorfer M. V., Manji H. The pharmacological treatment of depression. Drug Ther. 325:1991;633-642.
41. Ravindrian A. V., Griffiths J., Merali Z., Anisman H. Lymphocyte subsets associated with major depression and dysthymia. Modification by antidepressant treatment Psychosom. Med. 57:1995;555-563.
42. Reed S. M., Glick J. W. Fluoxetine and reactivation of the herpes simplex virus. Am. J. Psychol. 148:1991;949-950.
43. Richelson E. Synaptic effects of antidepressants. J. Clin. Psychol. 16(Suppl. 2):1996;1S-9S.
44. 2A) receptor desensitization can occur without downregulation. J. Pharmacol. Exp. Ther. 275:1995;1638-1646.
45. 2 receptors. Neuropharmacology. 31:1992;881-893.
46. Schleifer S. J., Keller S. E., Meyerson A. T., Rashkin M. J., Davis K. L., Stein M. Lymphocyte function in major depression disorder. Arch. Gen. Psychol. 41:1996;484-486.
47. Schleifer S. J., Keller S. E., Siris S. G., Davis K. L., Stein M. Depression and immunity. Lymphocyte function in ambulatory depressed patients, hospitalized schizophrenic patients, and patients hospitalized for herniorrhaphy Arch. Gen. Psychol. 42:1985;129-133.
48. 7 receptor binding sites in rat hypothalamus. Sensitivity to chronic antidepressant treatment Mol. Pharmacol. 47:1995;99-103.
49. Sluzewska A., Rybakowski J. K., Laciak M., Mackiewicz A., Sobieska M., Wiktorowicz K. Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine. Ann. NY Acad. Sci. 762:1995;474-476.
50. Stoudemire A. Expanding psychopharmacologic treatment options for the depressed medical patient. Psychosomatics. 36:1995;S19-S26.
51. Stout S. C., Nemroff C. B. Stress and psychiatric disorders. Semin. Neurosci. 6:1994;271-280.
52. Wong D. T., Bymaster F. P., Horng J. S., Molloy B. B. A new selective inhibitor for uptake of serotonin into synaptosomes of rat brain. 3-(p-trifluoromethylphenoxy)-n-methyl-3-phenylpropylamine J. Pharmacol. Exp. Ther. 193:1975;804-811.